EZH2 promotes tumor progression by increasing VEGF expression in clear cell renal cell carcinoma

Clinical and Translational Oncology

Volumn 17, Issue 1, 2015, Pages 41-49

  Xu, Z Q ^a,b   Zhang, L ^b   Gao, B S ^a   Wan, Y G ^b   Zhang, X H ^b   Chen, B ^b   Wang, Y T ^a   Sun, N ^a   Fu, Y W ^a  

^a JILIN UNIVERSITY   (China)

^b Tongliao Hospital   (China)

Author keywords

Apoptosis; Clear cell renal cell carcinoma; EZH2; Proliferation; VEGF

Indexed keywords

EZH2 PROTEIN, HUMAN; GREEN FLUORESCENT PROTEIN; POLYCOMB REPRESSIVE COMPLEX 2; SMALL INTERFERING RNA; VASCULOTROPIN A; VEGFA PROTEIN, HUMAN;

AGED; APOPTOSIS; CELL CYCLE; CELL PROLIFERATION; CHEMISTRY; DISEASE COURSE; FEMALE; FLOW CYTOMETRY; GENE EXPRESSION REGULATION; GENE SILENCING; HUMAN; IMMUNOHISTOCHEMISTRY; KIDNEY CARCINOMA; KIDNEY TUMOR; MALE; METABOLISM; MIDDLE AGED; TISSUE MICROARRAY; TUMOR CELL LINE;

AGED; APOPTOSIS; CARCINOMA, RENAL CELL; CELL CYCLE; CELL LINE, TUMOR; CELL PROLIFERATION; DISEASE PROGRESSION; FEMALE; FLOW CYTOMETRY; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE SILENCING; GREEN FLUORESCENT PROTEINS; HUMANS; IMMUNOHISTOCHEMISTRY; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; POLYCOMB REPRESSIVE COMPLEX 2; RNA, SMALL INTERFERING; TISSUE ARRAY ANALYSIS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84925397109     PISSN: 1699048X     EISSN: 16993055     Source Type: Journal    
DOI: 10.1007/s12094-014-1195-5     Document Type: Article

References (22)

1. Cohen HT, McGovern FJ. Renal-cell carcinoma. N Engl J Med. 2005;353:2477–90.
2. Vinay K, Abul KA, Nelson F. Robbins and Cotran pathologic basis of disease. 7th ed. Philadelphia: Elsevier; 1999. p. 1016–9.
3. Lewis EB. A gene complex controlling segmentation in drosophila. Nature. 1978;276:565–70.
4. Vainchenker W, Delhommeau F, Constantinescu SN, Bernard OA. New mutations and pathogenesis of myeloproliferative neoplasms. Blood. 2011;118:1723–35.
5. Sahasrabuddhe AA, Chen X, Chung F, Velusamy T, Lim, Elenitoba-Johnson KS. Oncogenic Y641 mutations in EZH2 prevent Jak2/beta-TrCP-mediated degradation. Oncogene. 2014;. doi:10.1038/onc.2013.571.
6. Okosun J, Bodor C, Wang J, Araf S, Yang CY, Pan C, et al. Integrated genomic analysis identifies recurrent mutations and evolution patterns driving the initiation and progression of follicular lymphoma. Nat Genet. 2014;46:176–81.
7. Erdmann K, Kaulke K, Thomae C, Huebner D, Sergon M, Froehner M, et al. Elevated expression of prostate cancer-associated genes is linked to down-regulation of microRNAs. BMC Cancer. 2014;14:82.
8. Atala A. Re: long non-coding RNA H19 increases bladder cancer metastasis by associating with EZH2 and inhibiting E-cadherin expression. J Urol. 2013;190:2306.
9. Athanassiadou AM, Lazaris AC, Patsouris E, Tsipis A, Chelidonis G, Aroni K. Significance of cyclooxygenase 2, EZH-2 polycomb group and p53 expression in actinic keratosis and squamous cell carcinomas of the skin. Am J Dermatopathol. 2013;35:425–31.
10. Hanahan D, Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell. 1996;86:353–64.
11. Maroto P, Rini B. Molecular biomarkers in advanced renal cell carcinoma. Clin Cancer Res. 2014;20(8):2060–71.
12. Smits M, Mir SE, Nilsson RJ, van der Stoop PM, Niers JM, Marquez VE, et al. Down-regulation of miR-101 in endothelial cells promotes blood vessel formation through reduced repression of EZH2. PLoS One. 2011;6:e16282.
13. Hubaux R, Thu KL, Coe BP, MacAulay C, Lam S, Lam WL. EZH2 promotes E2F-driven SCLC tumorigenesis through modulation of apoptosis and cell-cycle regulation. J Thorac Oncol. 2013;8:1102–6.
14. Nakagawa S, Okabe H, Sakamoto Y, Hayashi H, Hashimoto D, Yokoyama N, et al. Enhancer of zeste homolog 2 (EZH2) promotes progression of cholangiocarcinoma cells by regulating cell cycle and apoptosis. Ann Surg Oncol. 2013;20(Suppl 3):S667–75.
15. Eble JN, Sauter G, Epstein JI. Tumours of the kidney. In: World Health Organization classification of tumours: pathology and genetics, tumours of the urinary system and male genital organs. Lyon: International Agency for Research on Cancer Press; 2004:9–43.
16. Li X, Wan L, Geng J, Wu CL, Bai X. Aldehyde dehydrogenase 1A1 possesses stem-like properties and predicts lung cancer patient outcome. J Thorac Oncol. 2012;7:1235–45.
17. Li X, Wan L, Shen H, Geng J, Nie J, Wang G, et al. Thyroid transcription factor-1 amplification and expressions in lung adenocarcinoma tissues and pleural effusions predict patient survival and prognosis. J Thorac Oncol. 2012;7:76–84.
18. Fussbroich B, Wagener N, Macher-Goeppinger S, Benner A, Falth M, Sultmann H, et al. EZH2 depletion blocks the proliferation of colon cancer cells. PLoS One. 2011;6:e21651.
19. Fluge O, Gravdal K, Carlsen E, Vonen B, Kjellevold K, Refsum S, et al. Expression of EZH2 and Ki-67 in colorectal cancer and associations with treatment response and prognosis. Br J Cancer. 2009;101:1282–9.
20. Xu K, Wu ZJ, Groner AC, He HH, Cai C, Lis RT, et al. EZH2 oncogenic activity in castration-resistant prostate cancer cells is polycomb-independent. Science. 2012;338:1465–9.
21. Jene-Sanz A, Varaljai R, Vilkova AV, Khramtsova GF, Khramtsov AI, Olopade OI, et al. Expression of polycomb targets predicts breast cancer prognosis. Mol Cell Biol. 2013;33:3951–61.
22. Ougolkov AV, Bilim VN, Billadeau DD. Regulation of pancreatic tumor cell proliferation and chemoresistance by the histone methyltransferase enhancer of zeste homologue 2. Clin Cancer Res. 2008;14:6790–6.